Abstracts tagged "interleukins-10"

Abstract Number: 846 • 2012 ACR/ARHP Annual Meeting
Preferential Binding to Elk-1 by SLE-Associated IL10 Risk Allele up-Regulates IL10 Expression
Daisuke Sakurai¹, Jian Zhao¹, Yun Deng¹, Jennifer A. Kelly², Kathy Moser Sivils², Kenneth M. Kaufman³, Elizabeth E. Brown on behalf of PROFILE⁴, Marta E. Alarcón-Riquelme on behalf of BIOLUPUS and GENLES network⁵, John B. Harley⁶, Sang-Cheol Bae⁷, Chaim O. Jacob⁸, Timothy J. Vyse⁹, Timothy B. Niewold¹⁰, Patrick M. Gaffney¹¹, Judith A. James², Robert P. Kimberly¹², Gary S. Gilkeson¹³, Diane L. Kamen¹⁴, Carl D. Langefeld¹⁵, Deh-Ming Chang¹⁶, Yeong Wook Song¹⁷, Weiling Chen¹, Jennifer M. Grossman¹, Bevra H. Hahn¹⁸ and Betty P. Tsao¹, ¹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³1Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Arthritis and Clinical Immunology, Centro de Genómica e Investigación Oncológica Pfizer-Universidad de Granada-Junta de Andalucía (GENYO), Granada, Spain and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁷Hanyang University Hospital for Rheumatic Disease, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, ⁸Department of Medicine,, Keck School of Medicine, University of Southern California, Los Angeles, CA, ⁹Divisions of Genetics and Molecular Medicine and Immunology,, King's College London, London, United Kingdom, ¹⁰Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹³Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ¹⁴Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ¹⁵Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ¹⁶Headquarter, National Defense Medical Center, Taipei, ¹⁷Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ¹⁸Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose:The established association between IL10 and multiple autoimmune diseases including SLE and elevated levels of IL-10 in SLE patients correlating with disease activity led us to fine-map…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].